Tryp Therapeutics announces initial patient enrollment in its Phase II clinical trial of a psilocybin-based compound (TRP-8802) for Binge Eating Disorder.
Tryp Therapeutics announces initial patient enrollment in its Phase II clinical trial of a psilocybin-based compound (TRP-8802) for Binge Eating Disorder.
Several major new deals in the psychedelics industry already in 2022 suggest that the industry could be moving on to its next phase of evolution.
Private psychedelics company, Terran Biosciences announces a drug development partnership with Sanofi S.A. for the development and commercialization of two late-stage CNS drugs.
Tryp Therapeutics closes the second tranche of its recently announced private placement for gross proceeds of CAD$3 million. Units are priced at CAD$0.15.
Dozens of psychedelic drugs to research. Several "generations" of R&D ahead. To say that we're early in the game with psychedelic drug research is an understatement.
Cybin announces a new clinical partner as it prepares for its Phase 1/2a clinical trial for CYB003.
Revitalist Lifestyle and Wellness announces 14th consecutive month of revenues growth and projects further growth across its network of 9 clinics.
Delic Holdings announces receiving a Health Canada 56 Research Exemption to conduct research on various psychedelic drugs.
Mydecine Innovations Group announces a share consolidation of 1 post-consolidation share for every 50 pre-consolidation shares.
Awakn Life Sciences reports that it now has three clinics in operation, including its new flagship clinic in London.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now